4331-29-7

Usage

Safety Profile

Mutation data reported. Whenheated to decomposition it emits toxic vapors of NOx.

InChI:InChI=1/C7H7N3/c8-5-2-1-3-6-7(5)10-4-9-6/h1-4H,8H2,(H,9,10)

Upstream product

• 64-18-6 formic acid 
• 66046-54-6 1,2,3-triaminobenzene dihydrochloride 
• 10597-52-1 4-nitro-benzimidazole 
• 606-22-4 2,6-dinitroaniline 
• 137654-47-8 4(7)-formylbenzimidazole 
• 3694-52-8 2,3-diamino-nitrobenzene 

Downstream Products

• 137654-50-3 N-<4(7)-benzimidazolyl>acetamide 
• 369652-68-6 2-[1⁽³⁾H-benzimidazol-4-ylamino]-3-nitrobenzoic acid 
• 902131-29-7 4-amino-1H-benzimidazole-1-carboxylic acid methyl ester 
• 902131-51-5 4-[3-(4-bromobenzyl)ureido]benzoimidazol-1-carboxylic acid methyl ester 
• 1029280-01-0 2-[1-(4-aminobenzoimidazol-1-yl)ethyl]-3-phenyl-3H-thieno[3,2-d]pyrimidin-4-one 
• 1380314-50-0 C₁₇H₁₉N₃O₂S 
• 1392240-16-2 C₁₄H₇F₅N₄O 
• 180587-75-1 (R)-diethyl (((1-(6-amino-9H-purin-9-yl)propan-2-yl)oxy)methyl)phosphonate 
• 137654-50-3 4(7)-acetamidobenzimidazole 
• 137654-49-0 1H-6,8-dimethylimidazo<4,5-h>quinoline 
• 137654-48-9 4⁽⁷⁾-(1-methyl-3-oxo-1-butenyl)aminobenzimidazole 
• 650638-11-2 (3H-benzoimidazol-4-yl)-hydrazine 

Relevant academic research and scientific papers

Investigating chelating sulfonamides and their use in metalloproteinase inhibitors

Matrix metalloproteinase inhibitors (MMPi) utilize zinc-binding groups (ZBGs) to chelate the catalytic Zn(ii) ion resulting in enzyme inhibition. Adapting findings from the literature of Zn(ii) ion sensors, we previously reported chelating sulfonamide inh

Benzimidazole-based anion receptors: Tautomeric switching and selectivity

Tautomeric switching is observed in a series of benzimidazole-based anion receptors upon addition of basic anions. An N-methylbenzimidazole based receptor selectively interacts with dihydrogen phosphate over a variety of other putative anionic guests via a combination of donated and accepted hydrogen bonds.

INHIBITORS OF CATECHOL O-METHYL TRANSFERASE AND THEIR USE IN THE TREATMENT OF PSYCHOTIC DISORDERS

The present invention relates to 4-pyridinone compounds which are inhibitors of catechol O-methyltransferase (COMT), and are useful in the treatment and prevention of neurological and psychiatric disorders and diseases in which COMT enzyme is involved. The present invention also relates to pharmaceutical compositions comprising these compounds and the use of these compounds and compositions in the prevention or treatment of such diseases in which COMT is involved

13C and 15N NMR spectra of aminobenzimidazoles in solution and in the solid state

The 13C [hexadeutero-dimethylsulfoxide (DMSO-d6), hexamethyl-phosphoramide (HMPA)-d18 and solid-state] and 15N (solid-state) NMR spectra of six C-aminobenzimidazoles have been recorded. The tautomerism of 4(7)-aminobenzimidazoles and 5(6)- aminobenzimidazoles has been determined and compared with B3LYP/6-311++G(d,p) calculations confirming the clear predominance of the 4-amino tautomer and the slight preference for the 6-amino tautomer. GIAO-calculated absolute shieldings compare well with experimental chemical shifts. Copyright

Compositions for dyeing keratinous fiber

A composition for dyeing keratinous fiber which includes incorporated therein an oxidative color-developing substance, an enzyme which reacts with oxygen as a substrate but does not evolve hydrogen peroxide, and a weak reducing agent.

N-substituted nonaryl-heterocyclic NMDA/NR2B antagonists

Compounds represented by Formula (I): 1or pharmaceutically acceptable salts thereof, are effective as NMDA NR2B antagonists useful for relieving pain.

Structure-antiviral activity relationship in the series of pyrimidine and purine N-[2-(2-phosphonomethoxy)ethyl] nucleotide analogues. 1. Derivatives substituted at the carbon atoms of the base

A series of dialkyl esters of purine and pyrimidine N-[2- (phosphonomethoxy)ethyl] derivatives substituted at position 2, 6, or 8 of the purine base or position 2, 4, or 5 of the pyrimidine base were prepared by alkylation of the appropriate heterocyclic base with 2- chloroethoxymethylphosphonate diester in the presence of sodium hydride, cesium carbonate, or 1,8-diazabicyclo[5,4,0]undec-7-ene (DBU) in dimethylformamide. Additional derivatives were obtained by the transformations of the bases in the suitably modified intermediates bearing reactive functions at the base moiety. The diesters were converted to the corresponding monoesters by sodium azide treatment, while the free acids were obtained from the diester by successive treatment with bromotrimethylsilane and hydrolysis. None of the PME derivatives in the pyrimidine series, their 6-aza or 3-deaza analogues, exhibited any activity against DNA viruses or retroviruses tested, except for the 5-bromocytosine derivative. Substitution of the adenine ring in PMEA at position 2 by Cl, F, or OH group decreased the activity against all DNA viruses tested. PMEDAP was highly active against HSV-1, HSV-2, and VZV in the concentration range (EC50) of 0.07-2 μg/mL. Also the 2-amino-6-chloropurine derivative was strongly active (EC50 = 0.1- 0.4 μg/mL) against herpes simplex viruses and (EC50 = 0.006-0.3 μg/mL) against CMV and VZV. PMEG was the most active compound of the whole series against DNA viruses (EC50 ~0.01-0.02 μg/mL), though it exhibited significant toxicity against the host cells. The base-modified compounds did not show any appreciable activity against DNA viruses except for 7-deazaPMEA (IC50 ~7.5 μg/mL) against HIV-1 and MSV. The neutral (diisopropyl, diisooctyl) diesters of PMEA were active against CMV and VZV, while the corresponding monoesters were inactive. The diisopropyl ester of the 2- chloroadenine analogue of PMEA showed substantially (10-100x) higher activity against CMV and VZV than the parent phosphonate. Also, the diisopropyl and diisooctyl ester of PMEDAP inhibited CMV and VZV, but esterification of the phosphonate residue did not improve the activity against either MSV or HIV.

New generation dopaminergic agents. 5. Heterocyclic bioisosteres that exploit the 3-OH-N1-phneylpiperazine dopaminergic template

The synthesis of several bioisoteric analogs based on the 3-OH-N1- phenylpiperazine dopamine D2 agonist template (i.e., 4) is described. The indolone (5) and 2-CF3-benzimidazole (13) were observed to have excellent affinity for the D2 receptor. Several D4 selective compounds were also identified. Molecular modeling studies and a putative bioactive conformation are discussed.

Synthesis and anticonvulsant activity of 3H-imidazo[4,5-c]-pyridazine, 1H-imidazo[4,5-d]pyridazine and 1H-benzimidazole analogues of 9-(2-fluorobenzyl)-6-methylamino-9H-purine

The 3H-imidazo[4,5-c]pyridazine, 1H-imidazo[4,5-d]pyridazine, and 1H-benzimidazole analogues of the potent anticonvulsant purine 9-(2-fluorobenzyl)-6-methylamino-9H-purine (1, 78U79) were synthesized and tested for anticonvulsant activity. The 3H-imidazo[4,5-c]pyridazines 8 and 9 were prepared in five stages from 3,4,5-trichloropyridazine (2). The 1H-imidazolo[4,5-d]pyridazine 15 was synthesized in four stages from 5-[(benzyloxy)methyl]-1,5-dihydro-4H-imidazo[4,5-d]pyridazin-4-one (10a). The benzimidazole analogues 18 and 20 were prepared from 2,6-dinitroaniline in three stages. These compounds were one-tenth or less as active as 1 in protecting rats against maximal electroshock-induced seizures.